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Abstract
Aims—Individualization of cancer chemotherapy based on the patient’s genetic makeup holds
promise for reducing side effects and improving efficacy. However, the relative contribution of
genetics to drug response is unknown.
Materials & methods—In this study, we investigated the cytotoxic effect of 29 commonly
prescribed chemotherapeutic agents from diverse drug classes on 125 lymphoblastoid cell lines
derived from 14 extended families.
Results—The results of this systematic study highlight the variable role that genetics plays in
response to cytotoxic drugs, ranging from a heritability of <0.15 for gemcitabine to >0.60 for
epirubicin.
Conclusion—Putative quantitative trait loci for cytotoxic response were identified, as well as
drug class-specific signatures, which could indicate possible shared genetic mechanisms. In
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addition to the identification of putative quantitative trait locis, the results of this study inform the
prioritization of chemotherapeutic drugs with a sizable genetic response component for future
investigation.
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Important progress continues to be made in the treatment of most common cancers, but
therapeutic benefit remains difficult to predict and severe or fatal adverse events occur
frequently. The Human Genome Project has fueled the notion that genetic information can
produce effective and cost-efficient selection of therapies for individual patients [1], but
validated genetic signatures that predict response to most chemotherapy regimens remain to
be identified. Numerous genes potentially influence drug response, but current candidate
gene approaches aimed at discovering and characterizing pharmacogenetic effects are
limited by the requirement of a priori knowledge about the genes involved [2]. While
genome-wide association analyses represent unbiased approaches to trait mapping, the
moderate size of most clinical trials often limits this avenue for cancer pharmacogenomics
discovery [3]. Furthermore, many pharmacogenomic studies are performed with the unstated
and untested assumption that the drug response is a heritable trait, potentially wasting scarce
clinical and analytical resources if that assumption proves false.
In response to these limitations, we undertook a thorough, unbiased pharmacogenomic
assessment of cytotoxic effects of the majority of US FDA approved cancer compounds. We
used an in vitro model system to determine the heritability of drug-induced cell killing and
performed genome-wide analysis for pharmacologic quantitative trait loci (pQTL).
Promising results have been obtained previously using similar systems on a smaller scale,
supporting the notion that genetics can influence cytotoxic activity of some drugs [4–7]. In
addition to preliminary identification of putative response loci, the results of this study
inform the prioritization of chemotherapeutic drugs with a sizable genetic response
component for future investigation.
Materials & methods
Cell lines
The Centre d’Etude du Polymorphisme Humain (CEPH) cell lines are a set of immortalized
lymphoblastoid cell lines (LCLs) collected from normal, healthy human volunteers, which
are commercially available from the Coriell Cell Repositories (NJ, USA). This collection is
unique because the cell lines were established from large multigenerational families and
there is comprehensive, publically available genotype data available for these cells lines [7].
A total of 125 LCLs contained within the following CEPH family pedigrees were used in
this study: 35, 45, 1334, 1340, 1341, 1345, 1350, 1362, 1408, 1420, 1447, 1451, 1454 and
1459. These cell lines were chosen to provide at least 80% power to detect a heritability (h2)
of 0.3 or greater.
Fresh growing lymphoblastoid cells were received from Coriell in T25 flasks and were
further cultured in Roswell Park Memorial Institute medium 1640 containing 2 mM L-
glutamine (Gibco, CA, USA) and 15% fetal bovine serum (Sigma-Aldrich Co, MO, USA;
lot 107K8408) at 37°C, 5% CO2 in a NUAIRE autoflow infrared direct heat CO2 incubator
(Labrepco, PA, USA). No media antibiotics were used for these studies. Frozen aliquots of
each cell line were stored in liquid nitrogen for use throughout the study. Individual cell
lines were counted in a Z1 Coulter Particle Counter (Beckman Coulter, CA, USA) and
plated at 4000 cells/well (45 µl per well) in a 384-well plate containing the drugs (as noted
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in the ‘Drugs’ section below). One cell line was assayed per 384-well plate and replicates of
each cell line were performed using a new frozen aliquot grown at a different time.
Individual cells lines were assayed in random order across assay plates (e.g., not assayed by
family or family structure) to limit the influence of any unknown systematic assay bias on
the results. Furthermore, prior to commencement of these studies, seeded cultures of cells
were plated in 384-well plates containing vehicle controls and assayed as described below.
Minimal edge effects were observed and the fluorescence intensity of the outer edge wells
were consistently within one standard deviation of the mean of the entire plate.
Drugs
Gemcitabine, epirubicin hydrochloride, temozolomide, teniposide and topotecan were
obtained from LKT laboratories (MN, USA). All other drugs were purchased from Sigma.
Drugs were diluted in either H2O or dimethyl sulphoxide (DMSO) depending on solubility.
Drugs with poor solubility in water, 0.9% NaCl, or DMSO and those requiring in vivo
metabolic activation were not assessable. Final concentrations, after addition of 45 µl of
cells and media, of DMSO were 1% or less in all wells, except for the negative control wells
which contained 10% DMSO. Drug doses used were selected based on the results of testing
a small number (n < 6) of unrelated cell lines with a broad range of doses. From that data,
four doses spanning the observed viability range were selected for further study on the
complete 125 cell line panel. A subset of drugs could not be dosed high enough to reach
maximal cytotoxic effect due to drug solubility issues. Details about drugs and vehicles
utilized are shown in Supplementary Figure 1 (see
www.futuremedicine.com/doi/suppl/10.2217/pgs.11.92). Four different doses of each drug
and four vehicle controls (0.1% DMSO, 1.0% DMSO, 10% DMSO and water) were plated
in quadruplicate (5 µl/well) on a 384-well plate using a Biomek 3000 (Beckman Coulter)
liquid handling robot. Drug-containing 384-well plates were sealed and stored at −80°C and
thawed once before use in the cytotoxicity assay. Drug- and control-well treatment positions
in the plate were held constant throughout the study.
Cytotoxicity measurements
The cytotoxic effects of the 29 drugs were determined using the nontoxic, colorimetric
Alamar Blue assay (BIosource, CA, USA) [7]. Briefly, 45 µl of fresh cultures of cells were
seeded in 384-well plates (Corning #3712) at a density of 4000 cell/well containing 5 µl of
varying doses of 29 drugs. Plates were incubated for 72 h at 37°C, 5% CO2 before the
addition of 5 µl of Alamar Blue (Biosource International, CA, USA). Plates were incubated
an additional 24 h before fluorescence intensity was measured using an excitation filter of
535 nm and emission filter of 595 nm. Plates were read from above the plate for 0.1 s using
Multimode Detection Software v2.1.0.17 on a DTX880 plate reader (Beckman Coulter). For
each drug, percent viability was measured relative to the appropriate untreated control wells
using the following formula: mean raw fluorescence units (RFU) of four drug-treated wells
– mean RFU of four 10% DMSO wells/mean RFU of four vehicle only wells – mean RFU
of four 10% DMSO wells
A 10% DMSO treatment condition was used as a negative control (i.e., 0% viability) in the
calculation of viability for each cell line to control for background fluorescence due to
serum, media or cellular debris. For each drug, viability was calculated relative to the
vehicle only control well that was appropriate for that drug (i.e., 0.1% DMSO, 1.0% DMSO
or water). For each of 125 LCLs, four doses of each drug were assayed in quadruplicate
wells. Then, for each cell line, this entire process was repeated with cells from a separately
seeded frozen culture.
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Cell cytotoxicity assay data conversion—Data were cleaned with a careful quality
control pipeline prior to analysis. First, assay plates were checked for inappropriately mass
cell death by comparing the wells RFUs with a threshold. Any plates whose 90th percentile
of RFU values was below 2000 were removed, as the majority of the cells on these plates
were dead for reasons unrelated to drug effect. Second, outliers on plates were identified and
removed with a coefficient of variation screen, checking for values outside the range defined
by the 99.5% coefficient of variation above and below the mean. Third, errant values in the
10% DMSO negative control were identified and removed, since an errant negative control
reading greatly influences the viability calculation used (presented above) for further
analysis. Again, a coefficient of variation threshold was used. Fourth, vehicle only wells that
serve as positive controls in the assays were checked for deviant values. Just as with the
DMSO negative controls, errant values in the vehicle only wells would greatly impact
viability calculations and downstream analysis. There is high correlation between the mean
vehicle viabilities for each cell line across all vehicles used (0.78 < r < 1.0), and these
relationships are used to screen the data for errors. This provides a means to check if any
one particular vehicle is far from the expectation. To test for outliers in vehicle well values,
we performed a simple linear regression for each of the viabilities from one vehicle on the
others. Therefore, each mean vehicle viability is involved as the response for four
regressions. Any response that was more than one standard deviation away from its
predicted value was considered deviant and was removed. If a particular response was
deviant in three or four, out of the four regressions, it was removed. After careful quality
control, average percentage viability was calculated from the two independent plates, with
four technical replicates on each plate. In addition, for each vehicle used, growth rate was
calculated as previously described [8].
Box plots for the viabilities observed for each drug across all doses used for 125 cell lines
within the 14 families are shown for each drug, in Supplementary Figure 2. Box plots for the
viabilities for each drug at all dose points across all individual cell lines are included in
Supplementary Figure 3.
Heritability analysis—To estimate the proportion of variation in dose response due to
inherited factors, variance components analysis as implemented in MERLIN® 1.1.2 [9,101]
was used to calculate heritability. Heritability of the growth rate for each vehicle was
calculated, and the heritability calculation of each drug and dose treatment combination was
adjusted for the growth rate for the appropriate vehicle by using growth rate as a covariate in
the variance components analysis. For each drug, the highest heritability for any dose is
given in Figure 1. The doses that correspond to the highest heritability are listed in
Supplementary Figure 4 for drugs with putatively significant linkage results.
Genotype data & error checking—Genotype data for each cell line was downloaded
from version 10 of the CEPH database [102,10] using error checked markers. Genetic map
information was downloaded from the Marshfield database [103,11]. Error checking for
Mendelian incompatibility, misspecified relationships and unlikely recombinations was
performed, as previously described [7]. A combined total of 8269 SNPs and microsatellite
markers were used for linkage analysis.
Technical and biological reproducibility was high for our assay, with the average correlation
for each cell line across replicates being 0.9067 (standard deviation = 0.0835). The average
coefficient of variation for all drugs and vehicle and control replicates across all replicates
was 6.57% (standard deviation = 6.28%).
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Linkage analysis—While the current study was designed to estimate heritability, the
publicly available data was also used for linkage analysis to identify putative regions of the
genome linked to the drug response traits. Recognizing the limited power of the current
study to detect pQTLs, we relied on a permutation and replication approach to prioritize
pQTLs within and across drug response phenotypes. Given these limitations, it is crucial that
these results be interpreted as ‘hypothesis generation’ rather than strict ‘hypothesis testing’
results.
Phenotypes of interest for linkage analysis were defined as cell viability at each drug and
dose point, resulting in a total of 116 total phenotypes from the current study. For each
phenotype, nonparametric linkage analysis was performed using MERLIN because it is
robust to nonnormality in the phenotypic variables of interest. As described in detail in
Abecasis et al. MERLIN constructs a likelihood ratio test for linkage based on inheritance
vectors [9]. For quantitative traits, scores used to calculate the likelihood ratio test are
defined as follows:
where S(ν) is the score for each inheritance vector, Sallele(ν) is the score for each founder
allele, yi is the phenotype for each individual, μ is the mean phenotype for the population,
and ν is the list of individuals who carry a specific founder allele such that the score for
each inheritance vector is the summation of the squared score for each founder allele, and
the score for each found allele is the sum of square deviation from all individuals that carry
that allele.
For each phenotype of interest, QTL maps were constructed by displaying the logarithm of
odds scores from the likelihood ratio tests across each chromosome, and QTL maps for
different doses of the same drugs were overlaid. A complete set of QTL maps for each drug,
by chromosome can be found in Supplementary Figure 5. This approach does not directly
account for potential dependence between dose point phenotypes for individual cell lines,
this expected dependence is incorporated into our prioritization pipeline described below.
Results prioritization & peak identification—To estimate the probability of obtaining
false-positive evidence of linkage for each drug and dose combination under the null
hypothesis of no linkage to observed phenotypes, we conducted gene-dropping permutations
using MERLIN. Marker data were simulated under the null hypothesis of no linkage or
association to observed phenotypes while retaining the same pedigree structures, maps,
marker allele frequencies, and missing data patterns. We simulated 10,000 replicates for
each phenotype of interest (discussed above), resulting in a total of 1.16 million simulated
datasets, and conducted linkage analyses as described earlier for each replication. Based on
these simulations, null distributions for each phenotype, for each chromosome were
constructed.
Empirical results from the permutation testing were used to ascribe putative significance to
the linkage results. The pQTL results from the dose of each drug that resulted in the highest
heritability estimate were used to prioritize results for replication in additional doses.
Using the permutation distributions constructed across all the chromosomes for each
phenotype evaluated, logarithm (base 10) of odds (LOD) score cut-offs corresponding to p-
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values less than or equal to 0.05 for each drug at the highest heritability dose were found,
and used to define significant LOD score peaks. A complete list of LOD score significance
cut-offs (for all drug and dose combinations) can be found in Supplementary Figure 6. The
average LOD score cut-off indicating ‘significant linkage’ across all drugs, doses and
chromosomes was 1.44. This significance cut-off corresponds to a family-wise error rate of
5% for each drug and dose tested (such that the false-positive rate is divided between
chromosomes for each drug), and treats drug/dose combinations as independent tests. These
LOD score cut-offs were used to define significant peaks for each drug, where a region was
considered significant if the highest LOD score in the region was greater than or equal to the
permutation testing derived cut-offs. A complete list of significant peaks is included in
Supplementary Figure 4.
In addition to defining these putatively statistically significant peaks, suggestive pQTLs
were identified using the permutation distributions. LOD score cut-offs that define
suggestive peaks were determined as the minimum LOD score to achieve a p-value of 0.05
at each chromosome (not corrected for the entire genome). The average LOD score cut-off
indicating ‘suggestive linkage’ across all drugs, doses and chromosomes was 0.601. Cut-offs
that define suggestive linkage for each drug and dose combination are also listed in
Supplementary Figure 4.
The region encompassing each significant pQTL was defined as the contiguous
chromosomal segment with LOD scores above a minimum value that was either: the peak
LOD score minus one or the LOD score cut-off that defines suggestive linkage, whichever is
higher. The LOD score cut-offs used for defining the bounds of pQTLs are listed in
Supplementary Figure 6.
Results
We investigated the cytotoxic effect of 29 commonly prescribed chemotherapeutic agents
from diverse drug classes (Table 1) on 125 LCLs derived from 14 extended families from
the CEPH collection. A high-throughput assay, employing a 384-well plate format and the
fluorescent viability indicator Alamar Blue, was used to determine the cytotoxicity of the
drugs on the LCLs. Viability after drug treatment was calculated relative to cells treated with
vehicle only. For each drug, four doses were chosen in an effort to capture the exponential
portion of the cytotoxicity curve.
Heritability was calculated for each drug and dose outcome, as well as growth rate for each
control vehicle in the current study using variance-components methods as implemented in
MERLIN [9]. The heritability of cellular growth rate was <0.14 across the drug vehicles,
and heritability was calculated with and without using cell growth as a covariate for the
cytotoxic response traits (Figure 1).
Results of drug cytotoxicity assays showed variation across families and individual cell lines
(Supplementary Figures 2 & 3). The maximum heritability of the drugs studied varied from
0.06 to 0.64. In total, 19 of the 29 drugs yielded a maximum heritability of >0.3. Overall,
only two of the 29 drugs had a maximum heritability at or below that observed for drug
vehicle.
Nonparametric linkage analysis was performed to identify pQTLs for each drug at each
dose. A permutation approach was employed to define LOD score cutoffs indicating
significant and suggestive evidence for linkage (see “Results prioritization & peak
identification”). To prioritize results, primary emphasis was placed on the dose of each drug
that resulted in the highest heritability estimate for cytotoxicity, with supporting evidence
provided by results in other doses.
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A total of 31 regions with peak LOD scores above the putative significance cut-offs were
observed among the pQTL results for 26 of the drugs at the dose demonstrating the highest
heritability (Supplementary Figure 4). Of the three drugs for which no significant LOD
scores were found, two drugs (gemcitabine and fludarabine) had the lowest heritabilities of
all the drugs tested, while the third (cytarabine) showed moderate heritability.
For all significant peaks identified in the dose point with the highest heritability, these
regions were evaluated for replication at a suggestive or significant level in additional dose
points for the drug. A region was considered replicated if any portion of the region that
defined the pQTL showed evidence for linkage at an additional dose. Of the 31 significant
pQTLs across all drugs, nine replicated at least a suggestive level at one additional dose; 13
replicated at two additional doses; and six replicated at three additional doses (i.e., all four
dose points evaluated). In addition, for regions with suggestive linkage in the highest
heritability dose, the pQTL mapping results from additional doses were evaluated for
replication at a suggestive or significant level. There were a total of 31 regions that reached
significant linkage. In addition, a total of 589 peaks reached ‘suggestive’ cut-offs in the
highest heritability dose. Of these suggestive regions, 333 showed evidence of at least
suggestive linkage in at least one additional dose. Figure 2 displays the results of this
prioritization for significant peaks, as well as suggestive peaks that replicate in a minimum
of one additional dose. Details of the peaks identified are found in the supplemental
materials (Supplementary Figures 4 & 7).
Pharmacologic QTLs were observed to occur in similar locations across doses for a given
drug, and also across drugs families with common chemical structures or presumed
mechanisms of action. For example, overlapping pQTLs were found in the same region of
chr7 for the fluoropyrimidines 5-fluorouracil and floxuridine, two drugs thought to share a
similar mechanism of action (Figure 3). Peak co-localization was observed for other drug
classes as well, specifically the DNA crosslinkers, vinca alkaloids and anthracyclines
(Figure 2). Regions with significant peak LOD scores for growth in the three different drug
vehicle controls did not overlap peaks for any of the significant drug cyotoxicity results
(Data Not Shown), indicating that genetic effects on growth rates of the different cell lines
are not likely to be responsible for the loci identified by the cytotoxicity analysis. These
pQTL results were formally evaluated for over-representation in drugs of similar
mechanistic classes. The hypergeometric distribution was used to test whether significant
pQTLs were overrepresented in mechanistic drug classes, and indicated there is a
nonrandom distribution of peaks amongst classes (p < 0.05).
Discussion
The results of this study have several important implications for the field of cancer
pharmacogenomics. Heritability estimates varied widely across the drugs studied, which
implies quantitative differences in the role that genetic polymorphism plays in response to
chemotherapeutic agents. The majority of drugs (66%) had a maximum heritability of >0.3,
a threshold value for many genetic studies of complex human traits. This provides an
objective basis for the prioritization of whole genome discovery studies in valuable clinical
trial DNA samples. Indeed, if the results of the study presented here using this model system
can be extended to future in vivo studies, the application of genome wide association studies
to a drug with low heritability is unlikely to produce significant results.
By using multiple drugs within and across classes, evaluating common and unique pQTLs
across drug classes may reveal important aspects of the genetic etiology of drug response. In
addition, as replication has become the gold standard in human genetics applications,
evaluation of different dose points for a single drug, other members of drug classes or
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structurally similar drugs could provide a measure of internal replication for the pQTLs
identified. This replication approach can be used to help prioritize regions for follow-up in
future studies. Similarly, further study of pQTLs that are common within and across drug
classes may help elucidate potential unifying downstream mechanisms of action of the
drugs. However, given our limited power to determine genome-wide significant linkage
peaks, it should be noted that the results of the current study should be evaluated in future,
well powered studies for finer genetic mapping.
As with any model system, the limitations of the system must be considered when
interpreting the results. This in vitro model of drug-induced cytotoxicity simplifies the effect
of these drugs on cancer patients in clinical settings, where pharmacokinetic and other
factors will also play a role in patient response. For the results of this study to have clinical
relevance, the genetic pathways of chemotherapeutic response in host or tumor response in
vivo would need to be similar to what was seen in this study. Unfortunately, performing a
study with similar aims to the one presented here using intact, extended human families
would not be feasible due to ethical, logistical and cost hurdles.
While LCLs have been frequently used as a model system for uncovering the genetics of
gene expression [12], radiation response [13] and drug induced cytotoxicity [4–7], a recent
study [8] highlighted the need for proper study design and interpretation of the data. In order
to limit the effect of technical and biological noise on the results of this study, each drug and
dose measurement was performed in quadruplicate and was then repeated from a separately
seeded culture of LCLs. Technical and biological reproducibility for the assay was
extremely high, with a strong correlation among replicate measures (r = 0.9067). In addition,
the average coefficient of variation for all drugs and vehicle controls across all replicates
was 6.57% (standard deviation = 6.28%), indicating low variation across replicates. We also
included baseline growth rate, calculated for each vehicle control as a factor in our variance
components analysis, which was itself minimally heritable (h2 < 0.14). Furthermore, testing
for over-representation of pQTLs within drug classes suggests that drugs with similar
chemical structures had similar cytotoxic response, indicating that LCL cytotoxicity was
specific to each drug and not an artifact of the experimental design. Unfortunately, we did
not test for Ebstein–Barr virus copy number levels in our assay, and thus this remains a
limitation of the study.
The results of this study lay the groundwork for future studies to uncover the underlying
genes and variants influencing chemotherapeutic response. Whole-genome association
studies, using LCLs or DNA derived from clinical trials should be undertaken for drugs
found to have the highest heritability. This phenotype selection approach provides a clear
justification for where investment in extensive genomic analysis should be prioritized to
reach the goal of effective selection of therapy for individual patients.
Conclusion
The promise of pharmacogenomics is the individualization of cancer chemotherapy based on
the patient’s genetic makeup. However, the relative contribution of genetics to drug
response for specific chemotherapeutic drugs is largely unknown. By systematically
investigating 29 common prescribed chemotherapeutic agents using an in vitro model
system, we have been able to estimate the proportion of cytotoxic response that is
attributable to genetic factors as well as identify putative QTLs. The results of this our study
highlight the variable role that genetics plays in response to cytotoxic drugs, ranging from a
heritability of <0.15 for gemcitabine to >0.60 for epirubicin. In this study we were also able
to identify several putative significant QTLs, many of which replicated across drug doses.
These results are useful for the prioritization of chemotherapeutic drugs and genomic
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regions for further studies using complementary methods such as further in vitro studies, use
of animal models or clinical research.
Executive summary
▪ Pharmacogenomics holds promise for individualizing cancer treatment by
reducing the risk of adverse events and nonresponse.
▪ No systematic study has been performed to determine the relative
contribution of genetics on cytotoxic response across this broad of a set of
chemotherapeutic drugs.
Materials & methods
▪ The study described here used a systematic, in vitro approach to determine
the influence of genetic factors on cytotoxic response of 29 chemotherapeutic
drugs at several drug doses.
Results
▪ The relative contribution of genetic factors (heritability) to drug response
varied widely across drugs, from <0.15 (gemcitabine) to >0.60 (epirubicin).
▪ The results of our analysis identified several quantitative trait loci including
31 putative significant linkage peaks, nine of which replicated in additional
doses.
▪ Significant correlation was observed between linkage peaks and drug
mechanistic class, indicating possible shared mechanism.
Discussion
▪ These results are valuable for the prioritization of chemotherapeutic drugs
and genomic regions for future studies using complementary methods such as
further in vitro studies, use of animal models or clinical research.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Maximum heritability observed over all doses for commonly used anticancer drugs as
well as vehicle only controls
Heritability estimates are presented both uncorrected and corrected for growth rate.
DMSO: Dimethyl sulphoxide; FCS: Fetal calf serum.
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Figure 2. Genome-wide patterns of quantitative trait loci for all drugs, arranged by mechanistic
classes
Each chromosome was partitioned into 25-cm regions. For each drug at the dose that
resulted in the highest heritability estimate, any putative significant pharmacologic
quantitative trait loci regions (log10 of odds > empirical significance cut-off) is indicated in
blue. Intensity of the shading is dependent on the total number of additional doses that
indicated a replicating signal at either a suggestive or significant level, with higher intensity
indicating higher numbers of doses. Regions that also had at least a suggestive
pharmacologic quantitative trait loci, as well as at least one additional replication in another
dose, are shown in green, where again intensity of the color represent a higher number of
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dose replications. Drugs are grouped according to their mechanism of actions, where the
groups are labeled as follows: Group (A): ribonucleotide reductase inhibitors; Group (B):
thymidylate synthase inhibitors; Group (C): DNA intercalators and topoisomerase 2
inhibitors; Group (D): microtubule destabilizers; Group (E): microtubule stabilizers; Group
(F): DNA crosslinkers; Group (G): topoisomerase 2 inhibitors; Group (H): other.
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Figure 3. Genome-wide quantitative trait loci map
(A) 5-fluorouracil and (B) floxuridine, two structurally and functionally related drugs. Each
chromosome is represented by a different color.
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Table 1
Drugs used in this study
Drug name Mechanism of action
Cladribine Ribonucleotide reductase inhibitor
Fludarabine Ribonucleotide reductase inhibitor
Gemcitabine Ribonucleotide reductase inhibitor
Azacitidine Ribonucleotide reductase inhibitor
Cytarabine Ribonucleotide reductase inhibitor
5-fluorouracil Thymidylate synthase inhibitor
Floxuridine Thymidylate synthase inhibitor
Epirubicin DNA intercalators and topoisomerase 2 inhibitors
Doxorubicin DNA intercalators and topoisomerase 2 inhibitors
Daunorubicin DNA intercalators and topoisomerase 2 inhibitors
Idarubicin DNA intercalators and topoisomerase 2 inhibitors








Etoposide Topoisomerase 2 inhibitors
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